How can we help?

Or log in to submit or review a request.

Articles in this section

Add and reactivate EPCS tokens in iPrescribe

Purpose: This article explains how to add and reactivate your EPCS tokens in iPrescribe.

Audience: Providers with an active iPrescribe account who completed iPrescribe self-registration through ID.me and activated EPCS.

To add a token, have your iPrescribe password, your ID.me Authenticator, and your OneSpan hard token ready.

Manage your EPCS tokens

Open Manage Authenticators

Use Manage Authenticators in the iPrescribe app to manage your tokens.

1. Tap the More tab in the bottom-right corner of your screen, then select Settings.

More Tab_Settings Link.png
More > Settings

2. Select Manage Authenticators.

mceclip1.png
Settings, Manage Authenticators option

The Token Manager screen lists your tokens. The ID.me Authenticator from your registration appears in this list. If you added tokens before, they appear in the list too.

Add a new token

iPrescribe prompts you to enter your login password and a 6-digit code from your ID.me Authenticator.

1. Enter the requested information, then tap Confirm.

mceclip2.png
EPCS Confirmation page,
Password, Code Generator, 6-digit security code

2. On the Token Manager screen, tap Add New Token.

mceclip1.png
Token Manager page, Add New Token

3. Tap the Token Type drop-down menu, and select OneSpan hard token.

4. Enter a nickname for the token.

5. Enter the token's serial number.

Token Serial Number Format
OneSpan (hard token) 8-digit number with no dashes (########)

6. Enter the temporary 6-digit code generated by the token.

7. Tap Add New Token.

mceclip2.png
Add New Tokens fields to fill out

Your token now appears on the Token Manager screen.

Reactivate a token

You can reactivate a disabled token.

1. Open the Token Manager screen using the steps in Open Manage Authenticators.

2. Tap Reactivate next to the token you want to reactivate.

The token appears in the list.

Was this article helpful?
6 out of 24 found this helpful

Comments

0 comments

Article is closed for comments.